Capricor completes U.S. marketing submission for lead candidate
Source: SeekingAlpha
2025-01-02 09:57:37 ET
More on Capricor Therapeutics, Nippon Shinyaku Co., Ltd., etc.
- Deramiocel's Promise Brightens Capricor's Outlook, With Strings Attached
- Capricor: Additional Deramiocel Data Bodes Well For Initiated Rolling BLA Submission
- Capricor Therapeutics, Inc. (CAPR) Q3 2024 Earnings Call Transcript
- Capricor wins key EU designations for the lead asset
- Capricor Therapeutics Q3 2024 Earnings Preview
Read the full article on Seeking Alpha
For further details see:
Capricor completes U.S. marketing submission for lead candidate
Nippon Shinyaku Co Ltd ADR
NASDAQ: NPPNY
NPPNY Trading
0.0% G/L:
$8.43 Last:
198 Volume:
$8.43 Open:
